

28 December 2023

BEXIMCO PHARMACEUTICALS LIMITED

Annual General Meeting Statement

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBB6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that all resolutions put before shareholders at the Company's Annual General Meeting ("AGM") held virtually on 28 December 2023 were duly passed.

The resolutions passed at the AGM included the approval of 35% cash dividend for the year ended on 30 June 2023. The cash dividend being 35% of the nominal value per ordinary share of Taka 10 (Taka 3.5 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders'/GDR holders' as on the date of record, i.e. 13 November 2023) on or before 25 January 2024. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.

The Annual Report for 2022-23 is available from the Company's website, which includes the audited accounts and a review of operations for the year ended on 30 June 2023.

For further information please visit www.beximcopharma.com or enquire to:

Beximco Pharma

Nazmul Hassan MP, Managing Director
Tel: +880 2 58611001, Ext. 20080

S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson
Tel: +44 (0) 20 3470 0470

FTI Consulting

Simon Conway / Victoria Foster Mitchell
Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5700 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMPPGBWPUPWUBR